Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.9 EUR | +1.27% | -4.85% | -35.66% |
06-27 | Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing | MT |
06-20 | Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.66% | 1.71B | - | ||
+4.57% | 96.72B | A- | ||
+5.66% | 41.43B | A- | ||
-12.80% | 32.7B | B- | ||
+80.99% | 29.06B | A | ||
-15.53% | 15.38B | C | ||
-8.70% | 12.97B | B- | ||
-12.22% | 11.36B | D+ | ||
+183.25% | 9.9B | D | ||
+3.60% | 8.93B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZLAB Stock
- 1ZL Stock
- Ratings Zai Lab Limited